218 related articles for article (PubMed ID: 19350814)
1. [Progress in the study of antitumor drug targeting on the Ras signaling pathway].
Zhu YJ; Jiang FC
Yao Xue Xue Bao; 2009 Jan; 44(1):1-10. PubMed ID: 19350814
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs.
Kohno M; Pouyssegur J
Prog Cell Cycle Res; 2003; 5():219-24. PubMed ID: 14593716
[TBL] [Abstract][Full Text] [Related]
3. RAS: target for cancer therapy.
Saxena N; Lahiri SS; Hambarde S; Tripathi RP
Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
[TBL] [Abstract][Full Text] [Related]
4. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
5. In search of novel molecular targets in cancer: the diacyglycerol pathways.
Lorenzo PS
Hawaii Med J; 2004 Oct; 63(10):318-9, 321. PubMed ID: 15570721
[No Abstract] [Full Text] [Related]
6. Cancer targets in the Ras pathway.
Rodriguez-Viciana P; Tetsu O; Oda K; Okada J; Rauen K; McCormick F
Cold Spring Harb Symp Quant Biol; 2005; 70():461-7. PubMed ID: 16869784
[TBL] [Abstract][Full Text] [Related]
7. Targeting RAS signalling pathways in cancer therapy.
Downward J
Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
[TBL] [Abstract][Full Text] [Related]
8. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
9. New druggable targets in the Ras pathway?
Matallanas D; Crespo P
Curr Opin Mol Ther; 2010 Dec; 12(6):674-83. PubMed ID: 21154159
[TBL] [Abstract][Full Text] [Related]
10. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
Blum R; Kloog Y
Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
[TBL] [Abstract][Full Text] [Related]
11. Targeting new anticancer drugs within signalling pathways regulated by the Ras GTPase superfamily (Review).
Ramírez De Molina A; Rodríguez-González A; Lacal JC
Int J Oncol; 2001 Jul; 19(1):5-17. PubMed ID: 11408916
[TBL] [Abstract][Full Text] [Related]
12. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
Sacco E; Spinelli M; Vanoni M
Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
[TBL] [Abstract][Full Text] [Related]
13. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
[TBL] [Abstract][Full Text] [Related]
14. New microtubule-inhibiting anticancer agents.
Chen SM; Meng LH; Ding J
Expert Opin Investig Drugs; 2010 Mar; 19(3):329-43. PubMed ID: 20141350
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
Lerner EC; Hamilton AD; Sebti SM
Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
17. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.
Cakir M; Grossman AB
Expert Opin Ther Targets; 2009 Sep; 13(9):1121-34. PubMed ID: 19637976
[TBL] [Abstract][Full Text] [Related]
18. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design.
Ramírez de Molina A; Rodríguez-González A; Lacal JC
Cancer Lett; 2004 Apr; 206(2):137-48. PubMed ID: 15013519
[TBL] [Abstract][Full Text] [Related]
19. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.
Chinnaiyan P; Allen GW; Harari PM
Semin Radiat Oncol; 2006 Jan; 16(1):59-64. PubMed ID: 16378908
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
